Company intelligence / Profile preview

Novelty Nobility

Pangyo, South Koreanoveltynobility.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company has multiple programs in development, including NN3201 (an antibody-drug conjugate targeting c-Kit for cancer) and NN2101 (an anti-c-kit antibody for retinal diseases). They recently joined JLABS Korea to develop NN4101, a bispecific antibody targeting c-Kit and VEGF.

Therapeutic areas: OncologyOphthalmology
Modalities: Antibody-based therapeuticsBispecific antibodiesAntibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

6 assets

NN3201

5 more assets in the full pipeline.

Partnerships

GC BiopharmaJohnson & Johnson (JLABS Korea)

Beyond the preview

Go deeper on Novelty Nobility.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novelty Nobility.